Ascletis Pharma just reported promising preclinical results from a new weight-loss drug combination: ASC47 (a first-in-class, fat-targeting small molecule) paired with ASC31 (a novel GLP-1R/GIPR dual agonist).
The results hint at a treatment strategy that could outperform some of today’s leading obesity drugs.
The Science Behind the Combo
- ASC31:
- In-house developed dual agonist targeting GLP-1R and GIPR.
- Shows strong activity in obese mice and favorable pharmacokinetics in primates.
- Built on Ascletis’ Ultra-Long-Acting Platform (ULAP) for injectable and oral peptides. - ASC47:
- A thyroid hormone receptor beta (THRβ) selective small molecule.
- Injected once monthly under the skin.
- Specially designed for adipose (fat tissue) targeting, ensuring high local concentrations without spilling over into unwanted areas.
Together, these two mechanisms — metabolic control plus direct fat targeting — could deliver more powerful and durable weight-loss outcomes.
The Mouse Study: Head-to-Head Results
The experiment compared two groups of diet-induced obese (DIO) mice over 14 days:
- ASC47 (low dose) + ASC31 (low dose)
- ASC47 (low dose) + tirzepatide (low dose)
Results:
- ASC47 + ASC31: 44.8% total body weight reduction
- ASC47 + tirzepatide: 38.1% reduction
- That’s a 17.6% improvement in weight loss (p=0.02).
Why It Matters
- Obesity market is crowded: GLP-1 drugs like Wegovy and Mounjaro dominate, but patients need alternatives with better safety, tolerability, and fat-specific targeting.
- Muscle preservation is key: Most GLP-1 drugs reduce both fat and lean mass. ASC47’s adipose-targeting could help protect muscle tissue while driving fat loss.
- Differentiation opportunity: If results hold in humans, Ascletis’ combo could stand apart from existing treatments.
What’s Next
Ascletis is building a broad obesity pipeline with small molecules and peptides, including:
- ASC30: a once-daily oral GLP-1R agonist (lead program).
- ASC31: injectable dual GLP-1R/GIPR agonist.
- ASC47: fat-targeted THRβ agonist.
CEO Jinzi Jason Wu summed it up:
“The significant weight reduction demonstrated in this animal model suggests the potential for meaningful differentiation compared to currently marketed obesity treatments.”
Key Takeaway
While still in the preclinical stage, the data show that ASC31 + ASC47 may outperform a GLP-1 powerhouse like tirzepatide — at least in mice.
If that advantage translates to humans, Ascletis could carve out a new niche in the next generation of obesity therapies.
